Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAUSE perioperative NOAC management study
NL-OMON44377Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of dabigatran, rivaroxaban and apixaban in Atrial fibrillation (AFib) (3 cohorts), sponsored by Amsterdam University Medical Center. Primary endpoints: Major bleeding and Arterial thromboembolism. Started May 2018; status: active, not recruiting.
02
Drugs
dabigatranrivaroxabanapixaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NL-OMON44377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44377.